Studies of Millimeter-Wave Diffraction Devices and Materials. Phase III.

1986 ◽  
Author(s):  
Eugene R. Leach ◽  
Milton R. Seiler ◽  
Jennifer I. Halman
Keyword(s):  
Millimeter Wave ◽  
Wave Diffraction ◽  
Phase Iii

Fine structure of millimeter-wave diffraction emission. I

1985 ◽  
Vol 28 (10) ◽  
pp. 888-894
Author(s):  
A. A. Vertii ◽  
I. V. Ivanchenko ◽  
A. V. Nesterenko ◽  
N. A. Popenko ◽  
A. I. Tsvyk ◽  
...  
Keyword(s):  
Fine Structure ◽  
Millimeter Wave ◽  
Wave Diffraction

scholarly journals Millimeter-wave diffraction by a photo-induced plasma grating

1995 ◽  
Vol 43 (9) ◽  
pp. 2288-2290 ◽  
Author(s):  
V.A. Manasson ◽  
L.S. Sadovnik ◽  
A. Moussessian ◽  
D.B. Rutledge
Keyword(s):  
Millimeter Wave ◽  
Wave Diffraction

Millimeter wave diffraction antenna based on continuous phase correction

2012 ◽  
Vol 24 (3) ◽  
pp. 739-742
Author(s):  
陈鑫 Chen Xin ◽  
潘文武 Pan Wenwu ◽  
薛长江 Xue Changjiang ◽  
余川 Yu Chuan ◽  
屈劲 Qu Jin ◽  
...  
Keyword(s):  
Millimeter Wave ◽  
Wave Diffraction ◽  
Continuous Phase ◽  
Phase Correction

scholarly journals Millimeter‐wave diffraction‐loss model based on over‐rooftop propagation measurements

ETRI Journal ◽  
2020 ◽  
Vol 42 (6) ◽  
pp. 827-836
Author(s):  
Kyung‐Won Kim ◽  
Myung‐Don Kim ◽  
Juyul Lee ◽  
Jae‐Joon Park ◽  
Young Keun Yoon ◽  
...  
Keyword(s):  
Millimeter Wave ◽  
Wave Diffraction ◽  
Diffraction Loss ◽  
Loss Model ◽  
Model Based

RTS,S/AS01, a vaccine targeting pre-erythrocytic stages of Plasmodium falciparum

2017 ◽  
Vol 1 (6) ◽  
pp. 533-537
Author(s):  
Lorenz von Seidlein ◽  
Borimas Hanboonkunupakarn ◽  
Podjanee Jittmala ◽  
Sasithon Pukrittayakamee
Keyword(s):  
Protective Efficacy ◽  
Age Groups ◽  
Sub Saharan Africa ◽  
Phase Iii ◽  
European Medicines Agency ◽  
Older Children ◽  
Pivotal Phase ◽  
Malaria Epidemiology ◽  
Maximum Benefit ◽  
Sub Saharan

RTS,S/AS01 is the most advanced vaccine to prevent malaria. It is safe and moderately effective. A large pivotal phase III trial in over 15 000 young children in sub-Saharan Africa completed in 2014 showed that the vaccine could protect around one-third of children (aged 5–17 months) and one-fourth of infants (aged 6–12 weeks) from uncomplicated falciparum malaria. The European Medicines Agency approved licensing and programmatic roll-out of the RTSS vaccine in malaria endemic countries in sub-Saharan Africa. WHO is planning further studies in a large Malaria Vaccine Implementation Programme, in more than 400 000 young African children. With the changing malaria epidemiology in Africa resulting in older children at risk, alternative modes of employment are under evaluation, for example the use of RTS,S/AS01 in older children as part of seasonal malaria prophylaxis. Another strategy is combining mass drug administrations with mass vaccine campaigns for all age groups in regional malaria elimination campaigns. A phase II trial is ongoing to evaluate the safety and immunogenicity of the RTSS in combination with antimalarial drugs in Thailand. Such novel approaches aim to extract the maximum benefit from the well-documented, short-lasting protective efficacy of RTS,S/AS01.

Rome I versus Rome II; Overlap in patients enrolled in tegaserod phase III clinical trials for irritable bowel syndrome (IBS)

2001 ◽  
Vol 120 (5) ◽  
pp. A284-A284
Author(s):  
B NAULT ◽  
S SUE ◽  
J HEGGLAND ◽  
S GOHARI ◽  
G LIGOZIO ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Irritable Bowel Syndrome ◽  
Phase Iii ◽  
Phase Iii Clinical Trials ◽  
Irritable Bowel ◽  
Rome I
Sign in / Sign up

Export Citation Format

Share Document